Related Experiment Video
Updated: Mar 7, 2026
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
Danuta M Skowronski1,2, Catharine Chambers1, Suzana Sabaiduc1
1British Columbia Centre for Disease Control, Vancouver, Canada.
Abstract:
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.
More Related Videos
12:09Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Published on: November 22, 2017
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
Related Concept Videos
01:51Vaccinations
01:28Antimicrobial Effectiveness